CN105999249A - 具有γ干扰素的抗原呈递癌症疫苗 - Google Patents

具有γ干扰素的抗原呈递癌症疫苗 Download PDF

Info

Publication number
CN105999249A
CN105999249A CN201610301904.7A CN201610301904A CN105999249A CN 105999249 A CN105999249 A CN 105999249A CN 201610301904 A CN201610301904 A CN 201610301904A CN 105999249 A CN105999249 A CN 105999249A
Authority
CN
China
Prior art keywords
cells
melanoma
ifn
apoptotic
autophagic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610301904.7A
Other languages
English (en)
Chinese (zh)
Inventor
安德鲁.康福思
罗伯特.迪尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeoStem Oncology LLC
Original Assignee
California Stem Cells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Stem Cells Inc filed Critical California Stem Cells Inc
Publication of CN105999249A publication Critical patent/CN105999249A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201610301904.7A 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗 Pending CN105999249A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161549681P 2011-10-20 2011-10-20
US61/549681 2011-10-20
US201261594304P 2012-02-02 2012-02-02
US61/594304 2012-02-02
CN201280051821.7A CN103957925A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280051821.7A Division CN103957925A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗

Publications (1)

Publication Number Publication Date
CN105999249A true CN105999249A (zh) 2016-10-12

Family

ID=48141460

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201610301904.7A Pending CN105999249A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗
CN201280051821.7A Pending CN103957925A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗
CN201610218244.6A Withdrawn CN105861437A (zh) 2011-10-20 2012-10-22 抗原呈递癌症疫苗
CN201510706438.6A Pending CN105288602A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗
CN201280051799.6A Pending CN103917246A (zh) 2011-10-20 2012-10-22 抗原呈递癌症疫苗

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN201280051821.7A Pending CN103957925A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗
CN201610218244.6A Withdrawn CN105861437A (zh) 2011-10-20 2012-10-22 抗原呈递癌症疫苗
CN201510706438.6A Pending CN105288602A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗
CN201280051799.6A Pending CN103917246A (zh) 2011-10-20 2012-10-22 抗原呈递癌症疫苗

Country Status (11)

Country Link
US (2) US20140308316A1 (https=)
EP (2) EP2768519A4 (https=)
JP (2) JP2014530627A (https=)
KR (2) KR20150016200A (https=)
CN (5) CN105999249A (https=)
AU (2) AU2012325758A1 (https=)
CA (2) CA2852960A1 (https=)
HK (2) HK1201175A1 (https=)
IL (2) IL232172A0 (https=)
SG (4) SG11201401631VA (https=)
WO (2) WO2013059784A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865830B1 (fr) 2004-01-30 2006-05-19 Neopost Ind Systeme d'affranchissement de courrier a mode d'impression externe securise
AU2012325758A1 (en) * 2011-10-20 2014-04-24 Neostem Oncology, Llc Antigen presenting cancer vaccine with gamma interferon
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
CN107109365A (zh) * 2014-07-17 2017-08-29 布莱恩·J·赫尔尼奇 多剂量注射用树突状细胞疫苗的制备及用于阻断her2和her3的联合治疗
CN109416925A (zh) * 2016-05-05 2019-03-01 南托米克斯有限责任公司 检查点失效和使检查点失效的方法
AU2018222737B2 (en) * 2017-02-17 2021-03-25 Aivita Biomedical, Inc. Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells
WO2024107624A1 (en) * 2022-11-14 2024-05-23 Shattuck Labs, Inc. Methods of overcoming resistance to checkpoint inhibitor therapies
CN118441033B (zh) * 2024-04-24 2025-06-20 广西医科大学 HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106778A1 (en) * 2001-12-21 2004-06-03 Fagan Richard Joseph Interferon gamma-like protein
WO2006047515A2 (en) * 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
US20080031900A1 (en) * 2006-06-30 2008-02-07 Baylor Research Institute Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same
CN101808636A (zh) * 2007-07-06 2010-08-18 e-生物有限公司 黑色素瘤的治疗

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105618C (en) * 1992-09-07 2009-11-03 Kazuyasu Nakamura Humanized antibodies to ganglioside gm2
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
EP1056834A2 (en) 1998-02-20 2000-12-06 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
DK1224264T3 (da) 1999-10-15 2010-05-10 Baylor Res Inst Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
RU2313365C2 (ru) * 2001-11-29 2007-12-27 Дандрит Байотек А/С Фармацевтическая композиция для индукции иммунной реакции у человека
CN1443778A (zh) * 2002-03-13 2003-09-24 上海中信国健药业有限公司 一种黑色素瘤相关抗原的单克隆抗体及其用途和药物组合物
KR101374091B1 (ko) 2005-07-29 2014-03-17 프로비던스 헬스 앤드 서비시즈, 오레곤 수포에 담긴 불완전 리보솜 생성물（ＤＲｉｂｂｌｅ） 및 면역 반응을 자극하기 위해 이를 이용하는 방법
US8076308B2 (en) * 2005-11-07 2011-12-13 British Columbia Cancer Agency Inhibition of autophagy genes in cancer chemotherapy
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
AR060424A1 (es) 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
AU2012325758A1 (en) 2011-10-20 2014-04-24 Neostem Oncology, Llc Antigen presenting cancer vaccine with gamma interferon

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106778A1 (en) * 2001-12-21 2004-06-03 Fagan Richard Joseph Interferon gamma-like protein
WO2006047515A2 (en) * 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
US20080031900A1 (en) * 2006-06-30 2008-02-07 Baylor Research Institute Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells
CN101808636A (zh) * 2007-07-06 2010-08-18 e-生物有限公司 黑色素瘤的治疗
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same

Also Published As

Publication number Publication date
EP2768519A2 (en) 2014-08-27
JP2014533938A (ja) 2014-12-18
EP2768519A4 (en) 2015-07-01
HK1201176A1 (en) 2015-08-28
CA2852967A1 (en) 2013-04-25
IL232172A0 (en) 2014-06-30
CA2852960A1 (en) 2013-04-25
NZ623917A (en) 2016-09-30
CN105861437A (zh) 2016-08-17
KR20150004791A (ko) 2015-01-13
IL232173A0 (en) 2014-06-30
AU2012325764A1 (en) 2014-04-24
NZ623915A (en) 2016-02-26
KR20150016200A (ko) 2015-02-11
US20140314814A1 (en) 2014-10-23
HK1201175A1 (en) 2015-08-28
WO2013059778A2 (en) 2013-04-25
CN103957925A (zh) 2014-07-30
US9555058B2 (en) 2017-01-31
WO2013059784A1 (en) 2013-04-25
SG10201508535RA (en) 2015-11-27
JP2014530627A (ja) 2014-11-20
EP2768534A1 (en) 2014-08-27
SG11201401631VA (en) 2014-05-29
SG10201602424RA (en) 2016-05-30
US20140308316A1 (en) 2014-10-16
WO2013059778A3 (en) 2013-07-04
CN105288602A (zh) 2016-02-03
SG11201401632WA (en) 2014-05-29
AU2012325758A1 (en) 2014-04-24
CN103917246A (zh) 2014-07-09
EP2768534A4 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
US11096996B2 (en) Cancer vaccines and vaccination methods
US9555058B2 (en) Antigen presenting cancer vaccine
Panelli et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
Hatfield et al. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy
Li et al. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy
AU2023208190B2 (en) Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
EP2809775B1 (en) Pluripotent germ layer origin antigen presenting cancer vaccine
Hüttner et al. Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells
HK1230080A1 (en) Antigen presenting cancer vaccine with gamma interferon
US20060073589A1 (en) Rapid generation of activated mononuclear antigen presenting cells from monocytes
NZ623917B2 (en) Antigen presenting cancer vaccine
Dahlfrancis In Vitro Effects of the Second-Generation Proteasome Inhibitor Carfilzomib on Human Monocyte-Derived Dendritic Cells
HK1218928B (en) Cancer vaccines and vaccination methods
HK1190920A (en) Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1230080

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161012

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1230080

Country of ref document: HK